Table 4 Correlations between forkhead box A1 (FOXA1) expression, clinicopathological parameters and immunohistochemical markers in luminal* breast carcinomas carcinomas
ParameterNo.Sub-groupFOXA1neg(%)FOXA1pos(%)p Value
Size128T18 (11)64 (89)0.5298
T29 (18)40 (82)
T31 (14)6 (86)
Grade127I2 (13)13 (87)0.9857
II7 (14)43 (86)
III8 (13)54 (87)
Type129IDC12 (14)75 (86)0.8681
ILC3 (12)22 (88)
Other2 (12)15 (88)
LVI1285 (11)39 (89)0.7868
+12 (14)72 (86)
LN metastasis1253 (17)15 (83)0.1144
+15 (18)68 (82)
PR1302 (13)13 (87)>0.9999
+16 (14)99 (86)
p5312911 (11)91 (89)0.0598
+7 (26)20 (74)
Topo2A129Low9 (15)53 (85)>0.9999
High9 (13)58 (87)
MIB1128<10%8 (12)58 (88)0.7035
10–30%9 (16)49 (84)
>30%1 (25)3 (75)
Cyclin D1130Low1 (14)6 (86)0.2096
Intermediate6 (25)18 (75)
High11 (11)88 (89)
  • *Luminal cancers were defined according to the definition described by Nielsen et al.6

  • FOXA1pos, high level of FOXA1 expression (score greater than 3); FOXA1neg, low level of FOXA1 expression (score 3 or less); LN metastasis, lymph node metastasis; LVI, lymphovascular invasion; PR, progesterone receptor; LN metastasis, lymph node metastasis; LVI, lymphovascular invasion; Topo2A, topoisomerase IIα; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma.